AlessandroSantinMD

PubMed

• Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
  Stefania Bellone, Kyungjo Jeong, Mari Kyllesø Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman, Levent Mutlu, Cem Demirkiran, Tobias Max Philipp Hartwich, Ya...> ;Proceedings of the National Academy of Sciences of the United States of America. 2024 Apr 23
• Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
  Sangini S Sheth, Ji Eun Oh, Stefania Bellone, Eric R Siegel, Michelle Greenman, Levent Mutlu, Blair McNamara, Shefali Pathy, Mitchell Clark, Masoud Azodi, Gary Altwerg...> ;Clinical Cancer Research. 2024 Apr 9
• Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
  Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E Schwartz, Gautam G ...> ;British Journal of Cancer. 2024 Apr 1
• Targeting cervical cancer with anti-PD-1 antibodies: what is new?
  Michelle Greenman, Blair McNamara, Levent Mutlu, Alessandro D Santin> ;Expert Opinion on Biological Therapy. 2024 Mar 1
• Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
  Cem Demirkiran, Tobias Max Philipp Hartwich, Stefania Bellone, Diego Manavella, Michelle Greenman, Margherita Zipponi, Yang Yang-Hartwich, Kevin Yang, Silvia Coma, Jon...> ;Gynecologic Oncology. 2024 Feb 9
• Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.
  Bellone, S., Siegel, E., Scheim, D., Santin, A.> ;Gynecologic Oncology Reports. 2024 Feb 1
• Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID.
  Stefania Bellone, Eric E Siegel, Alessandro D Santin> ;Gynecologic Oncology Reports. 2023 Dec 1
• 2 citations
  Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.
  Scheim, D., Vottero, P., Hirsh, A., Santin, A.> ;International Journal of Molecular Sciences. 2023 Dec 1
• Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
  Blair McNamara, Michelle Greenman, Nicole Pebley, Levent Mutlu, Alessandro D Santin> ;Molecules. 2023 Nov 2
• 1 citations
  Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
  Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, Alla S Lisyanskaya, Sandro Pignata, Ignace Vergote, Francesco Raspagliesi, Gabe S Sonke, Michael Bir...> ;Gynecologic Oncology. 2023 Nov 1
• HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.
  Blair McNamara, Levent Mutlu, Michelle Greenman, Justin Harold, Alessandro Santin> ;Cancers. 2023 Aug 14
• 1 citations
  Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.
  Blair McNamara, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Alessandro D Santin> ;Gynecologic Oncology Reports. 2023 Aug 1
• Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.
  Blair McNamara, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Alessandro D Santin> ;Gynecologic Oncology Reports. 2023 Aug 1
• Computational Prediction of the Interaction of Ivermectin with Fibrinogen.
  Paola Vottero, Scott Tavernini, Alessandro D Santin, David E Scheim, Jack A Tuszynski, Maral Aminpour> ;International Journal of Molecular Sciences. 2023 Jul 14
• 3 citations
  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
  Julia H Gelissen, Naomi N Adjei, Blair McNamara, Levent Mutlu, Justin A Harold, Mitchell Clark, Gary Altwerger, Peter R Dottino, Gloria S Huang, Alessandro D Santin, M...> ;Annals of Surgical Oncology. 2023 Sep 1
• 2 citations
  Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
  Stefania Bellone, Blair McNamara, Levent Mutlu, Cem Demirkiran, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Eric R Siegel, Alessandro D Santin> ;International Journal of Molecular Sciences. 2023 May 17
• 1 citations
  Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
  Manavella, D., Blair McNamara, Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias Max Philipp Hartwich, Margherita Zipponi, Yang Yang-Hartwich, Cem...> ;Gynecologic Oncology. 2023 May 1
• 15 citations
  Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
  Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Bradley J Monk, Helen Mackay, Alessandro D Santin, David S Miller, Richard G Moore, Sally Baron-Hay, Isabelle ...> ;Journal of Clinical Oncology. 2023 Jun 1
• 1 citations
  Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
  Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, Alessandro D Santin, Emeline Colomba, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Sally E Baron-...> ;European Journal of Cancer. 2023 Jun 1
• 4 citations
  Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
  Justin Harold, Stefania Bellone, Diego D Manavell, Levent Mutlu, Blair McNamara, Tobias Max Philipp Hartwich, Margherita Zipponi, Yang Yang-Hartwich, Cem Demirkiran, M...> ;Gynecologic Oncology. 2023 Mar 1
• The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitr...
  Chanhee Han, Blair McNamara, Stefania Bellone, Justin Harold, Paola Manara, Tobias Max Philipp Hartwich, Levent Mutlu, Yang Yang-Hartwich, Margherita Zipponi, Cem Demi...> ;Gynecologic Oncology. 2023 Mar 1
• 1 citations
  Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
  Blair McNamara, Yifan Chang, Levent Mutlu, Justin Harold, Alessandro D Santin> ;Expert Opinion on Biological Therapy. 2023 Mar 1
• 8 citations
  Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian car...
  Manavella, D., Dennis Mauricio, Stefania Bellone, Levent Mutlu, Blair McNamara, Diego D Manavella, Cem Demirkiran, Miguel Skyler Z Verzosa, Natalia Buza, Pei Hui, Tobi...> ;Gynecologic Oncology. 2023 Mar 1
• 8 citations
  Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inh...
  Ryon P Graf, Kunal Shah, Natalie Danziger, Douglas I Lin, Julia Quintanilha, Gerald Li, James Haberberger, Jeffrey S Ross, Alessandro D Santin, Brian Slomovitz, Julia ...> ;International Journal of Gynecological Cancer. 2023 Apr 3
• 16 citations
  Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
  Ryan D Chow, Tai Michaels, Stefania Bellone, Tobias M P Hartwich, Elena Bonazzoli, Akiko Iwasaki, Eric Song, Alessandro D Santin> ;Cancer Discovery. 2023 Feb 6
• Join now to see all

Journal Articles

• Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)  
  Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology

Lectures

• A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018